TB-500 should not be assumed to mean full-length thymosin beta-4. A 2012 analytical paper identified the acetylated seven-residue fragment Ac-LKKTETQ in the material it examined, while primary sequence studies describe thymosin beta-4 as a 43-residue peptide. The useful question is which structure a particular document names, not whether two labels sound related (fragment study; human sequence study).
What did the original sequence research establish?
The 1981 work of Low and colleagues determined the amino acid sequence of thymosin beta-4 isolated from calf thymus. The paper describes 43 amino acid residues and an acetyl group at the amino terminus. That is evidence about the material characterized in that work, not an identification certificate for a modern catalog listing (primary publication).
Use the organism and material description when citing this paper. A bovine sequence study should not silently become a test of every product sold under a related name. The reference is useful precisely because it specifies what was examined; removing those details makes the citation less informative.
What does the human sequence paper add?
A 1987 study isolated a human cDNA clone from a library prepared using peripheral blood leukocytes from a patient. The clone contained the coding sequence for 43 amino acid residues. The researchers also examined thymosin beta-4 messenger RNA expression in several cell populations and cell lines (Gondo and colleagues).
This is molecular sequence and expression evidence. The source of the library is not a clinical trial sample count, and the paper is not a batch-purity assessment. Keep the type of evidence attached to the citation rather than allowing the presence of human-source material to change the study’s meaning.
What was identified in the TB-500 analytical paper?
Esposito and colleagues reported identification of the N-terminal acetylated 17–23 fragment of human thymosin beta-4 in the TB-500 material they examined. The sequence is written Ac-LKKTETQ. Their identification work used chromatography and high-resolution mass spectrometry; the abstract does not give the number of commercial lots tested (2012 primary study).
That finding is specific to the examined material. It is not evidence that every current listing called TB-500 contains the same structure. Equally, a contemporary listing using the term thymosin beta-4 does not change what the earlier analytical paper identified. Match the claim to the source’s scope.
Why do the fragment notation and terminal modification matter?
In the 2012 paper, 17–23 identifies the positions of the fragment within the parent sequence, and Ac identifies the N-terminal acetylation. The seven-residue sequence and its terminal modification are part of the authors’ chemical assignment, not optional wording that can be dropped without changing the description (analytical record).
When comparing records, copy the complete designation into your notes. Separate the parent name, fragment boundaries and terminal modification into distinct fields if that makes a mismatch easier to see. Do not expand a fragment name into a full-length identity simply because a search result places the two terms together.
What the evidence actually shows
Sequence determination, 1981: the material was thymosin beta-4 isolated from calf thymus. The structural endpoint was an amino acid sequence with 43 residues and an acetylated amino terminus. The accessible abstract does not state a total specimen count or an overall experimental duration; neither is inferred here (Low and colleagues).
Human coding sequence and expression, 1987: the study used a human leukocyte-derived cDNA library and investigated expression in additional cell populations. Its endpoints included the coding sequence and messenger RNA measurements. The abstract does not supply a complete sample count or overall duration. The source patient for the library should not be described as the entire experimental sample (primary abstract).
Analytical identification, 2012: the study characterized material labelled TB-500 and assigned Ac-LKKTETQ, the acetylated 17–23 fragment. The relevant endpoint was chemical identification. Product/lot counts and an overall duration are not stated in the abstract, so the report is not presented as a market survey or a longitudinal study (Esposito and colleagues).
Does a naming mismatch prove that a batch failed?
No batch verdict follows from comparing names alone. The papers establish different structural descriptions in their own experimental settings: full-length sequence work in 1981 and 1987, and a specified fragment assignment in 2012. They do not test an ETHOS batch.
A discrepancy between a label, specification and report is a reason to request clarification. Do not automatically call it a failed identity test, and do not resolve it by choosing whichever reference seems most convenient. First establish what was intended to be supplied and what the laboratory actually assigned.
Which documents should be compared?
Put the catalog designation, lot label and analytical report beside one another. Look for an explicit sequence or unambiguous structural designation, any fragment boundaries, terminal modifications, and the basis of the identity assignment. If the report only repeats the trade name, ask for the missing structural information rather than viewing repetition as independent confirmation.
The same care applies when reviewing the ETHOS tissue-biology research category. This article explains a literature naming distinction; it does not assign a full-length or fragment identity to an unresolved ETHOS TB500 listing. That assignment requires the relevant product and batch documentation.
How this relates to research materials
ETHOS uses “8X tested” to mean eight distinct tests before shipment, with batch COAs searchable through the public portal. Match the lot number first. The COA reading guide explains how to retain the named material and reported measurements together.
Keep identity separate from chromatographic purity and measured content. Our HPLC and mass spectrometry guide explains those different questions. Retain storage requirements and handling records with the label and report; do not turn one analytical result into an unsupported statement about later storage conditions.
Frequently asked questions
Is the fragment in the 2012 paper full-length thymosin beta-4?
No. The paper identifies the acetylated 17–23 fragment, Ac-LKKTETQ (primary abstract).
How long is the reference thymosin beta-4 sequence discussed here?
The cited bovine and human sequence work describes 43 residues (1981; 1987).
Does the article identify the contents of an ETHOS TB500 vial?
No. It explains published structural descriptions. The particular listing and lot need their own documentation.
What if the label and report use different names?
Ask for the exact structural designation and a lot-matched explanation. Do not infer equivalence or declare a failed test from the names alone.
Research use only. ETHOS materials are for laboratory research, not human or veterinary use. This article concerns chemical identity and evidence, not product effects or guidance on personal use.
Frequently asked questions
Is the fragment in the 2012 paper full-length thymosin beta-4?
No. The paper identifies the acetylated 17–23 fragment, Ac-LKKTETQ ( primary abstract ).
How long is the reference thymosin beta-4 sequence discussed here?
The cited bovine and human sequence work describes 43 residues ( 1981 ; 1987 ).
Does the article identify the contents of an ETHOS TB500 vial?
No. It explains published structural descriptions. The particular listing and lot need their own documentation.
What if the label and report use different names?
Ask for the exact structural designation and a lot-matched explanation. Do not infer equivalence or declare a failed test from the names alone.
